In summary, we conclude from our data that targeting the TNFR1/TRAF2/IKK/NFκB signal transduction pathway might be a strategy for inhibiting inflammation-related cell fusion events within a tumour as it could give rise to cancer cell ×normal cell hybrids that could exhibit novel properties. The gene discussed is NFKB1; the disease is cancer.